Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2018-05-22 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于更换持续督导保荐代表人的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the change of the continuous supervision sponsor representative for the company after its IPO listing. It details the replacement of a sponsor representative and includes a brief resume of the new representative. There is no financial data, no report or presentation attached, and no mention of voting results or other report types. This fits the category of a regulatory announcement about management or supervisory changes related to the IPO process, but it is not a direct management change in the company's board or senior management. Given the nature of the announcement, it best fits under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2018-05-22 Chinese
2017年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is titled as an announcement regarding the implementation of the 2017 annual equity distribution (dividend) plan of Betta Pharmaceuticals Co., Ltd. It details the dividend amount per 10 shares, the record date, the ex-dividend date, the dividend recipients, and the dividend payment method. It also references the shareholders' meeting resolution approving the dividend plan. The document is short (1452 characters) and focuses solely on the dividend distribution details without containing full financial statements or comprehensive financial performance data. Therefore, it is an announcement of dividend amount and payment details, fitting the category of Notice of Dividend Amount (DIV).
2018-05-15 Chinese
第二届监事会第十七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 17th meeting of the second Supervisory Board of Betta Pharmaceuticals Co., Ltd. It details the approval of adjustments to the 2018 stock option incentive plan, including changes in the number of options and the list of recipients. The document includes voting results and compliance statements with relevant laws and regulations. It does not contain financial statements or detailed financial performance data, nor is it a transcript, presentation, or report publication announcement. It is a regulatory announcement related to corporate governance and stock option plans, but it is not a management change announcement or a remuneration report. Given the nature of the content, it best fits under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-05-15 Chinese
独立董事关于第二届董事会第二十二次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on matters discussed at the 22nd meeting of the second board of directors of Betta Pharmaceuticals Co., Ltd. It focuses on the adjustment and granting of stock options under the 2018 stock option incentive plan. The content is about governance and approval of stock option plans, which is related to board/management decisions and governance practices. It is not a full financial report, earnings release, or regulatory filing. The document is relatively short (1824 characters) and is a formal opinion rather than a report or announcement of voting results. Therefore, it fits best under Board/Management Information (MANG), as it concerns board decisions and management-related approvals.
2018-05-15 Chinese
浙江天册律师事务所关于公司2018年股票期权激励计划授予与调整事项的法律意见书
Audit Report / Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2018 stock option incentive plan grant and adjustment matters of Betta Pharmaceuticals Co., Ltd. It details the legal procedures, approvals, and compliance related to the stock option plan, including board and shareholder meeting approvals, adjustments to grant recipients and quantities, and confirmation of compliance with relevant laws and regulations. The document is a standalone legal opinion on a specific corporate action (stock option incentive plan) and does not contain financial statements or audit results. It is not an annual report, audit report, or financial report. It is also not a regulatory announcement or a brief notice but a detailed legal opinion letter. Therefore, the most appropriate classification is Audit Report / Information (AR), as it relates to legal and compliance verification of a corporate action, which fits under audit/legal opinion reports rather than general regulatory filings or management announcements. FY 2018
2018-05-15 Chinese
2018年股票期权激励计划激励对象名单（调整后）
Remuneration Information Classification · 95% confidence The document is titled as the "2018 Stock Option Incentive Plan Incentive Object List (Adjusted)" for Betta Pharmaceuticals Co., Ltd. It lists detailed information about stock options granted to directors, senior management, and core technical/business personnel, including quantities and proportions. This is a disclosure related to stock option incentives for management and key personnel, which is a form of remuneration information. There is no indication of it being a full annual report, audit report, or other financial report. The document is not a brief announcement but a detailed list of incentive recipients and stock option allocations. Therefore, it fits best under the category of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors, including stock option plans.
2018-05-15 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.